Why Is HALOZYME THERAPEUTIC (HALO) Stock Down Today?

Halozyme Therapeutics shares fell 15.22% to $104.25 today, driven primarily by a downgrade from Leerink Partners. The firm cut its rating to Market Perform, citing limited upside potential and noting that recent quarterly results only marginally exceeded consensus estimates.

What Happened

Leerink Partners initiated the sell-off by downgrading Halozyme to Market Perform, arguing that the company’s recent performance offered marginal upside relative to market expectations. This action triggered a sharp decline in the stock price. In response, several other analysts maintained their positive outlooks while raising price targets. Evercore ISI Group maintained its Outperform rating and raised its price target to $125. Citizens maintained its Market Outperform rating and lifted its target to $149. Wells Fargo maintained an Equal-Weight rating and increased its target from $95 to $110.

The company also provided guidance on regulatory impacts, stating it anticipates zero to minimal royalty revenue impact through 2035 based on the Centers for Medicare and Medicaid Services final rule for the Medicare Drug Price Negotiation Program. Additionally, Halozyme confirmed that its Enhanze technology is included in Janssen’s Rybrevant Faspro, which recently received FDA accelerated approval for head and neck squamous cell carcinoma.

What The Data Shows

The stock opened at $115.66, a 5.9% gap down from the prior close of $122.96. The session high was $119.69 at 8:45 AM ET, while the low reached $104.00 at 12:00 PM ET. Volume stood at 2.3 million shares, which is 1.1 times the three-month daily average. Fundamentals show a market cap of $14.8 billion with a P/E ratio of 36.4. Revenue grew 41.2% over the trailing twelve months, and the net margin is 24.9%. The stock has a beta of 0.90 and trades within a 52-week range of $61.23 to $134.00.

Over the last 8 sessions, the stock declined 4.3% from $128.50 to $122.96. Recent insider activity includes six sells totaling $22.1 million in the last 90 days, with no buys. CEO Torley Helen sold shares on October 6, 2026, and director Matthew L. Posard sold on October 1 and September 16, 2026. Congressional records show one sell of $1,001 to $15,000 by Representative Ray Cisneros Jr. on September 29, 2026. The 52-week tape recorded one fresh high and 33 fresh lows on November 6, 2026.

What To Watch

Investors will monitor upcoming earnings reports and how the market digests the mixed analyst reactions following the Leerink downgrade.